Investments
2Partners & Customers
8About LFB Biomedicaments
LFB Biomedicaments is a manufacturer of pharmaceutical products. The company researches and develops plasma-derived medications to treat therapeutic areas of immunology, intensive care, hemostasis, and rare diseases.
LFB Biomedicaments Headquarters Location
3 Avenue des Tropiques
Courtaboeuf, 40 305,
France
+33 0169827004
LFB Biomedicaments Web Traffic
LFB Biomedicaments Rank
Latest LFB Biomedicaments News
Apr 9, 2021
||LFB Biomedicaments S.A., Kedrion S.p.A., Octapharma AG, Sanquin Plasma Products B.V Advanced report on Global Kawasaki Disease Treatment Market Added by Data Bridge Market Research, offers details on current and future growth trends pertaining to the business besides information on myriad regions across the geographical landscape of the Kawasaki Disease Treatment Market. The report also expands on comprehensive details regarding the supply and demand analysis, participation by major industry players and market share growth statistics of the business sphere. This comprehensive Kawasaki disease treatment industry research report includes a brief on these trends that can help the organizations operating in the industry to understand the market and strategize for their business expansion accordingly. The research report analyzes the market CAGR,Volume, industry share And size, demand and trend growth, key segments, and key drivers and restrains. New Players in the market are facing tough competition from established international Players as they struggle with technological innovations, reliability and quality issues. The report will answer questions about the current market developments and the scope of competition, opportunity cost and more. Download Exclusive Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this Industry @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-kawasaki-disease-treatment-market Kawasaki disease treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 6.80% in the above-mentioned research forecast period. The Major Players Covered In The Kawasaki Disease Treatment Market Are Takeda Pharmaceutical Company Limited, CSL, Grifols, S.A., ( Gamma Globulin, Monoclonal Antibodies, Steroids, NSAIDs), Kawasaki Disease Treatment Market By Route of Administration (Oral, Parenteral, Others), (Clinics, Hospitals, Homecare, Others), (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Kawasaki Disease Treatment Market By Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) For More Information Or Query Or Customization Before Buying Visit@ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-kawasaki-disease-treatment-market Global Kawasaki Disease Treatment Market Drivers: Rapid rise in incidence of kawasaki disease in the emerging countries and increase in adoption of intravenous immunoglobulin therapy in order to prevent or reduce the coronary artery problem are some factors driving the market growth. Moreover, increasing focus of market players towards the development of advanced treatment options and the underlining clinical trials using different drugs such as steroids and infliximab to treat the disease as the second line and tertiary treatment also boost up the market growth. Moreover, increasing research and development and rising healthcare expenditure act as opportunities for the market growth. Global Kawasaki Disease Treatment Market Restraints: Sometimes adverse effect related to the drugs, strict regulatory framework and high cost of biological therapy among others may hamper the global Kawasaki disease treatment market. Access Full Report @ https://www.databridgemarketresearch.com/reports/global-kawasaki-disease-treatment-market Insights of the Study Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the trocars market Market Penetration: Comprehensive information on the product portfolios of the top players in the Kawasaki disease treatment market To strategically profile key players and comprehensively analyze their market position in terms of ranking and core competencies, and detail the competitive landscape for market leaders The key findings and recommendations highlight crucial progressive industry trends in the Kawasaki disease treatment Market, thereby allowing players to develop effective long term strategies Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to products, segmentation and industry verticals. Kawasaki Disease Treatment Market Country Level Analysis Kawasaki disease treatment market is analysed and market size information is provided by country, treatment, route of administration, end-users and distribution channel as referenced above. The countries covered in the Kawasaki disease treatment market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa. On geographical estimation, North America accounts the largest market share due to the rising cases of Kawasaki disease in the U.S with reported 4,200 children in the U.S every year. Moreover, rising governmental concern towards the children health and increasing research and development activities is also boosting the growth of market. Asia-Pacific is expected to account for the largest market share owing to increase in incidence of acquired congenital heart disease caused due to Kawasaki disease. Moreover, increasing prevalence of KD in Japan with reported 1 affected child in every 100 children is another factor boosting the Asia Pacific market. Table Of Content: Executive Summary Global Kawasaki disease treatment Market: Growth and Forecast Global Kawasaki disease treatment Market: Company Share Global Kawasaki disease treatment Market: Regional Analysis North America Kawasaki disease treatment Market: An Analysis Europe Kawasaki disease treatment Market: An Analysis APAC Kawasaki disease treatment Market: An Analysis ROW Kawasaki disease treatment Market: An Analysis Global Kawasaki disease treatment Market: Market Dynamics Porter Five Force Analysis Company Profiles Points Covered in The Report: The points that are discussed within the report are the major market players that are involved in the Kawasaki disease treatment market. The complete profile of the companies is mentioned. The production, sales, future strategies, and the technological developments that they are making are also included within the report. The growth factors of the Kawasaki disease treatment market is discussed in detail wherein the different end users of the market are explained in detail. The application areas of the Kawasaki disease treatment market are also discussed thus giving a broad idea about the market to the clients. The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included. Reasons to buy this report: To get a comprehensive overview of the Kawasaki disease treatment To gain information about the top players in this industry, their product portfolios, and their key strategies. To gain insights about the major regional insights in which the Kawasaki disease treatment is flourishing. Recent industry trends and developments Potential and niche segments/regions exhibiting promising growth About Us: Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing sopan.gedam@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate. Contact:
LFB Biomedicaments Investments
2 Investments
LFB Biomedicaments has made 2 investments. Their latest investment was in GamaMabs Pharma as part of their Seed VC on September 9, 2013.
LFB Biomedicaments Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
9/30/2013 | Seed VC | GamaMabs Pharma | $4.2M | Yes | 1 | |
9/30/2013 | Series A |
Date | 9/30/2013 | 9/30/2013 |
---|---|---|
Round | Seed VC | Series A |
Company | GamaMabs Pharma | |
Amount | $4.2M | |
New? | Yes | |
Co-Investors | ||
Sources | 1 |
LFB Biomedicaments Acquisitions
1 Acquisition
LFB Biomedicaments acquired 1 company. Their latest acquisition was CAF-DCF on July 08, 2016.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
7/8/2016 | Acquired | 1 |
Date | 7/8/2016 |
---|---|
Investment Stage | |
Companies | |
Valuation | |
Total Funding | |
Note | Acquired |
Sources | 1 |
LFB Biomedicaments Partners & Customers
8 Partners and customers
LFB Biomedicaments has 8 strategic partners and customers. LFB Biomedicaments recently partnered with Xenothera on April 4, 2020.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
4/15/2020 | Partner | France | Odile Duvaux , President of XENOTHERA added : `` We are very pleased with this collaboration with LFB , a French pharmaceutical company well-versed in antibody technologies , that responded favourably to our request for urgent action in these times when the health emergency is the top priority . | 1 | |
2/20/2017 | Partner | ||||
6/30/2016 | Licensee | ||||
3/18/2016 | Vendor | ||||
2/20/2013 | Partner |
Date | 4/15/2020 | 2/20/2017 | 6/30/2016 | 3/18/2016 | 2/20/2013 |
---|---|---|---|---|---|
Type | Partner | Partner | Licensee | Vendor | Partner |
Business Partner | |||||
Country | France | ||||
News Snippet | Odile Duvaux , President of XENOTHERA added : `` We are very pleased with this collaboration with LFB , a French pharmaceutical company well-versed in antibody technologies , that responded favourably to our request for urgent action in these times when the health emergency is the top priority . | ||||
Sources | 1 |
LFB Biomedicaments Team
7 Team Members
LFB Biomedicaments has 7 team members, including current Chief Executive Officer, Denis DELVAL.
Name | Work History | Title | Status |
---|---|---|---|
Denis DELVAL | Chief Executive Officer | Current | |
Olivier Grellier | Chief Financial Officer | Current | |
David LOISON | Chief Financial Officer | Current | |
Hélène Guéry | DBV Technologies, Septodont, Pierre Fabre, Servier, and Centre Hospitalier Sud Francilien | Chief Marketing Officer | Current |
Benjamin MERY | Chief Executive Officer, Chief Financial Officer, Senior Vice President | Former |
Name | Denis DELVAL | Olivier Grellier | David LOISON | Hélène Guéry | Benjamin MERY |
---|---|---|---|---|---|
Work History | DBV Technologies, Septodont, Pierre Fabre, Servier, and Centre Hospitalier Sud Francilien | ||||
Title | Chief Executive Officer | Chief Financial Officer | Chief Financial Officer | Chief Marketing Officer | Chief Executive Officer, Chief Financial Officer, Senior Vice President |
Status | Current | Current | Current | Current | Former |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.